This study is looking at Rapamycin, a drug given by mouth once daily, to see if it's safe and well-tolerated for people with mild cognitive impairment (MCI) or early Alzheimer's disease (AD). You might receive Rapamycin or a placebo (an inactive pill). To join, you need to be between 55 and 89 years old, have a diagnosis of MCI or AD, and have amyloid positivity confirmed by a brain scan (Amyloid PET Imaging). The study will check for any side effects and changes in your glucose (blood sugar) and albumin (a protein in your blood) levels over 12 months. The study is currently recruiting about 40 participants, but its overall status is unclear.

Study design

This is an interventional study, meaning participants will receive either Rapamycin or a placebo. It plans to enroll 40 participants.

What's involved

You would have a screening period of up to 90 days, followed by 12 months of daily Rapamycin or placebo. There will be assessments after treatment and a final assessment 6 months later, for a total study duration of up to 90 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will have a post-treatment assessment within 14 days of the final study drug dose, and a final assessment 6 months after the final study drug dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.